EOM PHARMACEUTICALS ANNOUNCES ITS PRE-IND MEETING REQUEST WITH U.S. FDA TO EVALUATE PLANS FOR A PHASE 2 CLINICAL TRIAL OF ITS INVESTIGATIONAL DUAL-ACTING, BROAD-SPECTRUM IMMUNOMODULATOR IN COVID-19 PATIENTS

MONTVALE, N.J. – December 23, 2020 — EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, today announced it has filed a pre-Investigational New Drug Application (pre-IND) meeting request and complete pre-IND briefing documents with the U.S. Food and Drug Administration (FDA) to discuss the company’s plans to evaluate the safety and efficacy of its dual-acting, broad-spectrum immunomodulator drug candidate EOM613 in a Phase 2 clinical trial treating complications of hospitalized COVID-19 patients, including Acute Respiratory Distress Syndrome (ARDS).

The release as fetched from its publisher. eompharma.com ↗